Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials

R. Bouamar, N. Shuker, D. A. Hesselink, W. Weimar, H. Ekberg, B. Kaplan, C. Bernasconi, T. Van Gelder

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration-effect relationship for Tac is poorly defined. This study investigated whether Tac concentrations are associated with acute rejection in kidney transplant recipients. Data from three large trials were pooled. We used univariate and multivariate analysis to investigate the relationship between biopsy-proven acute rejection (BPAR) and Tac predose concentration at five time points (day 3, 10 and 14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced BPAR, giving an overall incidence of 10.4%. We did not find any significant correlations between Tac predose concentrations and the incidence of BPAR at the different time points. In the multivariate analysis, only delayed graft function (DGF) and the use of induction therapy were independently correlated with BPAR, with an odds ratio of 2.7 [95% CI: 1.8-4.0; p <0.001] for DGF and 0.66 [95% CI: 0.44-0.99; p = 0.049] for induction therapy. The other variables, including the Tac predose concentrations, were not statistically significantly associated with BPAR. We did not find an association between the Tac predose concentrations measured at five time points after kidney transplantation and the incidence of acute rejection occurring thereafter. Based on this study it is not possible to define the optimal target concentrations for Tac. The authors find no relationship between biopsy-proven acute rejection and tacrolimus predose concentrations, and posit that it is not possible to define the optimal target concentrations for tacrolimus.

Original languageEnglish (US)
Pages (from-to)1253-1261
Number of pages9
JournalAmerican Journal of Transplantation
Volume13
Issue number5
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Tacrolimus
Kidney Transplantation
Randomized Controlled Trials
Biopsy
Delayed Graft Function
Incidence
Multivariate Analysis
Drug Monitoring
Transplantation
Odds Ratio
Kidney

Keywords

  • Biopsy-proven acute rejection
  • pharmacodynamics
  • tacrolimus concentration
  • therapeutic drug monitoring
  • transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation : A pooled analysis from three randomized-controlled clinical trials. / Bouamar, R.; Shuker, N.; Hesselink, D. A.; Weimar, W.; Ekberg, H.; Kaplan, B.; Bernasconi, C.; Van Gelder, T.

In: American Journal of Transplantation, Vol. 13, No. 5, 05.2013, p. 1253-1261.

Research output: Contribution to journalArticle

Bouamar, R. ; Shuker, N. ; Hesselink, D. A. ; Weimar, W. ; Ekberg, H. ; Kaplan, B. ; Bernasconi, C. ; Van Gelder, T. / Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation : A pooled analysis from three randomized-controlled clinical trials. In: American Journal of Transplantation. 2013 ; Vol. 13, No. 5. pp. 1253-1261.
@article{2b568f7271e44b0f85a3681ae02a0d29,
title = "Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials",
abstract = "Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration-effect relationship for Tac is poorly defined. This study investigated whether Tac concentrations are associated with acute rejection in kidney transplant recipients. Data from three large trials were pooled. We used univariate and multivariate analysis to investigate the relationship between biopsy-proven acute rejection (BPAR) and Tac predose concentration at five time points (day 3, 10 and 14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced BPAR, giving an overall incidence of 10.4{\%}. We did not find any significant correlations between Tac predose concentrations and the incidence of BPAR at the different time points. In the multivariate analysis, only delayed graft function (DGF) and the use of induction therapy were independently correlated with BPAR, with an odds ratio of 2.7 [95{\%} CI: 1.8-4.0; p <0.001] for DGF and 0.66 [95{\%} CI: 0.44-0.99; p = 0.049] for induction therapy. The other variables, including the Tac predose concentrations, were not statistically significantly associated with BPAR. We did not find an association between the Tac predose concentrations measured at five time points after kidney transplantation and the incidence of acute rejection occurring thereafter. Based on this study it is not possible to define the optimal target concentrations for Tac. The authors find no relationship between biopsy-proven acute rejection and tacrolimus predose concentrations, and posit that it is not possible to define the optimal target concentrations for tacrolimus.",
keywords = "Biopsy-proven acute rejection, pharmacodynamics, tacrolimus concentration, therapeutic drug monitoring, transplantation",
author = "R. Bouamar and N. Shuker and Hesselink, {D. A.} and W. Weimar and H. Ekberg and B. Kaplan and C. Bernasconi and {Van Gelder}, T.",
year = "2013",
month = "5",
doi = "10.1111/ajt.12191",
language = "English (US)",
volume = "13",
pages = "1253--1261",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation

T2 - A pooled analysis from three randomized-controlled clinical trials

AU - Bouamar, R.

AU - Shuker, N.

AU - Hesselink, D. A.

AU - Weimar, W.

AU - Ekberg, H.

AU - Kaplan, B.

AU - Bernasconi, C.

AU - Van Gelder, T.

PY - 2013/5

Y1 - 2013/5

N2 - Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration-effect relationship for Tac is poorly defined. This study investigated whether Tac concentrations are associated with acute rejection in kidney transplant recipients. Data from three large trials were pooled. We used univariate and multivariate analysis to investigate the relationship between biopsy-proven acute rejection (BPAR) and Tac predose concentration at five time points (day 3, 10 and 14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced BPAR, giving an overall incidence of 10.4%. We did not find any significant correlations between Tac predose concentrations and the incidence of BPAR at the different time points. In the multivariate analysis, only delayed graft function (DGF) and the use of induction therapy were independently correlated with BPAR, with an odds ratio of 2.7 [95% CI: 1.8-4.0; p <0.001] for DGF and 0.66 [95% CI: 0.44-0.99; p = 0.049] for induction therapy. The other variables, including the Tac predose concentrations, were not statistically significantly associated with BPAR. We did not find an association between the Tac predose concentrations measured at five time points after kidney transplantation and the incidence of acute rejection occurring thereafter. Based on this study it is not possible to define the optimal target concentrations for Tac. The authors find no relationship between biopsy-proven acute rejection and tacrolimus predose concentrations, and posit that it is not possible to define the optimal target concentrations for tacrolimus.

AB - Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration-effect relationship for Tac is poorly defined. This study investigated whether Tac concentrations are associated with acute rejection in kidney transplant recipients. Data from three large trials were pooled. We used univariate and multivariate analysis to investigate the relationship between biopsy-proven acute rejection (BPAR) and Tac predose concentration at five time points (day 3, 10 and 14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced BPAR, giving an overall incidence of 10.4%. We did not find any significant correlations between Tac predose concentrations and the incidence of BPAR at the different time points. In the multivariate analysis, only delayed graft function (DGF) and the use of induction therapy were independently correlated with BPAR, with an odds ratio of 2.7 [95% CI: 1.8-4.0; p <0.001] for DGF and 0.66 [95% CI: 0.44-0.99; p = 0.049] for induction therapy. The other variables, including the Tac predose concentrations, were not statistically significantly associated with BPAR. We did not find an association between the Tac predose concentrations measured at five time points after kidney transplantation and the incidence of acute rejection occurring thereafter. Based on this study it is not possible to define the optimal target concentrations for Tac. The authors find no relationship between biopsy-proven acute rejection and tacrolimus predose concentrations, and posit that it is not possible to define the optimal target concentrations for tacrolimus.

KW - Biopsy-proven acute rejection

KW - pharmacodynamics

KW - tacrolimus concentration

KW - therapeutic drug monitoring

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84876946722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876946722&partnerID=8YFLogxK

U2 - 10.1111/ajt.12191

DO - 10.1111/ajt.12191

M3 - Article

C2 - 23480233

AN - SCOPUS:84876946722

VL - 13

SP - 1253

EP - 1261

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -